Targeting cancer stem cell propagation with palbociclib, a CDK4/6 inhibitor: Telomerase drives tumor cell heterogeneity.
about
Aspirin regulation of c-myc and cyclinD1 proteins to overcome tamoxifen resistance in estrogen receptor-positive breast cancer cells.Mitochondrial biomarkers predict tumor progression and poor overall survival in gastric cancers: Companion diagnostics for personalized medicine.Vitamin C and Doxycycline: A synthetic lethal combination therapy targeting metabolic flexibility in cancer stem cells (CSCs).Mitochondrial markers predict recurrence, metastasis and tamoxifen-resistance in breast cancer patients: Early detection of treatment failure with companion diagnostics.Mitochondrial mRNA transcripts predict overall survival, tumor recurrence and progression in serous ovarian cancer: Companion diagnostics for cancer therapy.Mitochondrial markers predict survival and progression in non-small cell lung cancer (NSCLC) patients: Use as companion diagnostics.Mitoketoscins: Novel mitochondrial inhibitors for targeting ketone metabolism in cancer stem cells (CSCs).A new mutation-independent approach to cancer therapy: Inhibiting oncogenic RAS and MYC, by targeting mitochondrial biogenesis.Targeting flavin-containing enzymes eliminates cancer stem cells (CSCs), by inhibiting mitochondrial respiration: Vitamin B2 (Riboflavin) in cancer therapy.Exploiting mitochondrial targeting signal(s), TPP and bis-TPP, for eradicating cancer stem cells (CSCs).CDK4/6 inhibition as maintenance and combination therapy for high grade serous ovarian cancer.Cancer stem cells (CSCs): metabolic strategies for their identification and eradication.Core signaling pathways in ovarian cancer stem cell revealed by integrative analysis of multi-marker genomics data.A mitochondrial based oncology platform for targeting cancer stem cells (CSCs): MITO-ONC-RX
P2860
Q33728292-45032502-E9DE-494B-8EC0-BA3C2E25E54AQ41817959-4A21DB35-AE48-4AF9-89D1-DBFF4DF7B712Q41911837-EFE68D73-C533-4426-8EB9-325D7E2FF84BQ41912547-51D682AC-AFAA-41C8-A471-F525082C8C9AQ41944791-02F8CE61-696B-4AC7-842E-67DFBD2575FFQ42366600-2C97749B-0422-488A-A4F4-8E66685991A6Q47097383-E56E9ED5-484C-4B1F-9581-32B095DAB091Q47131959-38A9E215-43C6-4154-9FD7-01DDDED5CD58Q47289203-688625C9-8F21-45BB-9CC5-26A5596532F4Q51768229-2A977540-10A1-4806-9999-6EF047B45A68Q52592862-6BB6E349-6EDF-4091-91D1-C3DA251D466CQ55254924-9D87DDC0-5CBB-4A92-8336-E2F8512A2F2DQ55520593-65DF799C-A2A5-44F5-8F6A-6B3EA8CBAF9CQ57148983-FC144965-2254-4939-9698-2A207649116B
P2860
Targeting cancer stem cell propagation with palbociclib, a CDK4/6 inhibitor: Telomerase drives tumor cell heterogeneity.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
2016年學術文章
@zh
2016年學術文章
@zh-hant
name
Targeting cancer stem cell pro ...... ives tumor cell heterogeneity.
@en
Targeting cancer stem cell pro ...... ives tumor cell heterogeneity.
@nl
type
label
Targeting cancer stem cell pro ...... ives tumor cell heterogeneity.
@en
Targeting cancer stem cell pro ...... ives tumor cell heterogeneity.
@nl
prefLabel
Targeting cancer stem cell pro ...... ives tumor cell heterogeneity.
@en
Targeting cancer stem cell pro ...... ives tumor cell heterogeneity.
@nl
P2093
P2860
P50
P356
P1433
P1476
Targeting cancer stem cell pro ...... ives tumor cell heterogeneity.
@en
P2093
Bela Ozsvari
Gloria Bonuccelli
Maria Peiris-Pages
P2860
P304
P356
10.18632/ONCOTARGET.14196
P407
P577
2016-12-25T00:00:00Z